Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines
given separately or combined for booster dosing at 4-6 years of age.
Sabin-IPV is an inactivated poliovirus vaccine
derived from attenuated strains, and its safety and efficacy are expected to be comparable to the inactivated polio vaccines derived from virulent strains, which are commonly used outside Japan.
Inactivated poliovirus vaccine
following oral poliovirus vaccine cessation.
The PPV and inactivated poliovirus vaccine
can be administered either IM or subcutaneously (SQ), but most authorities recommend the IM route for PPV and the SQ route for 1PV.
Takeda Pharmaceutical Company Limited ( Takeda ) today announced the voluntary discontinuation of the development of TAK-361S, a four-component, combination Diptheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine
(sIPV) that was in Phase 2 of clinical development.
In this single-blind, Phase II study, 609 infants were randomized 1:1 to receive either Hib-MenCY-TT or licensed Hib vaccine at 2, 4, and 6 months concomitantly with DTaP-Hep B-IPV (Pediarix[R] Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine
Combined) and pneumococcal 7-valent conjugate vaccine (Prevnar[R] Pneumococcal 7-valent Conjugate Vaccine Diphtheria CRM Protein).
DTaP denotes pediatric dose of diphtheria toxoid and tetanus toxoid and acellular pertussis; vaccine (this formulation is preferred for all doses of the series); IPV, inactivated poliovirus vaccine
(generally recommended for 2000); Hib, Haemophilus influenzae type b vaccine; MMR, measles-mumps-rubella combination vaccine; Td, adult does of diptheria toxoid and tetanus toxoid
During April 2016, the World Health Organization (WHO) coordinated global withdrawal of the type 2 component in oral poliovirus vaccine, replacing it with oral poliovirus vaccine containing only types 1 and 3, after introduction of inactivated poliovirus vaccine
The ACIP, an advisory group of the Centers for Disease Control and Prevention, recommended a sequential schedule of 2 doses of inactivated poliovirus vaccine
(IPV) followed by 2 doses of oral poliovirus vaccine (OPV), but also considered the all OPV or IPV schedules acceptable.
Complementing the switch from tOPV to bOPV, introduction of at least 1 dose of injectable, trivalent inactivated poliovirus vaccine
(IPV) into childhood immunization schedules reduces risks from and facilitates responses to cVDPV2 outbreaks.